Rosen Law Firm Investigates Tandem Diabetes Care Over Insulin Pump Recall
Rosen Law Firm, a prominent US law firm known for representing investors in securities class actions, is reportedly investigating potential claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM). Shareholders may be entitled to compensation through a contingency fee arrangement.
On August 7, 2025, Tandem Diabetes Care issued a voluntary medical device correction for select t:slim X2 insulin pumps. This announcement led to a significant drop in the company's stock price, with shares falling by 19.9% on the same day. The investigation by Rosen Law Firm follows this event and alleges that the company may have provided misleading business information to investors.
Rosen Law Firm has a proven track record in securities class actions. Notably, they secured the largest settlement against a Chinese company at the time. The firm focuses on cases where investors claim that a publicly traded company has concealed or misrepresented crucial facts, leading to the overvaluation of the company's stock and subsequent losses for shareholders.
While Rosen Law Firm is investigating potential claims against Tandem Diabetes Care, it is important to note that no lawsuit has been identified or announced against the company as of the latest information available in December 2023. Shareholders should stay informed about any developments in this matter. If you have information about a specific lawsuit, please provide details to facilitate further investigation.
